G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage oncology programs. Trilaciclib is a first-in-class FDA-designated “Breakthrough Therapy” designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer. Lerociclib is a differentiated oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in estrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer.